{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:22:43Z","timestamp":1767831763568,"version":"3.49.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML\/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 months (range, 13-362 months) after CML\/myeloproliferative neoplasm diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), melanoma (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), chronic lymphocytic leukemia (3%), hepatobiliary (3%), and other cancers (14%). Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients treated. The risk of second cancer was lower than expected (observed-to-expected ratio, 0.6; 95% confidence interval, 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.<\/jats:p>","DOI":"10.1182\/blood-2011-06-362889","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T00:14:44Z","timestamp":1313540084000},"page":"4353-4358","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":77,"title":["Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies"],"prefix":"10.1182","volume":"118","author":[{"given":"Dushyant","family":"Verma","sequence":"first","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara S.","family":"Strom","sequence":"additional","affiliation":[{"name":"Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Beth","family":"Rios","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Quintas-Cardama","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111810035425100_B1","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111810035425100_B2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111810035425100_B3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111810035425100_B4","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111810035425100_B5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results.","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111810035425100_B6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"24","key":"2019111810035425100_B7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111810035425100_B8","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111810035425100_B9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","article-title":"Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature.","volume":"33","author":"Guastafierro","year":"2009","journal-title":"Leuk Res"},{"issue":"6","key":"2019111810035425100_B10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14653240802317639","article-title":"Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.","volume":"10","author":"Seggewiss","year":"2008","journal-title":"Cytotherapy"},{"issue":"5B","key":"2019111810035425100_B11","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","article-title":"Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.","volume":"12","author":"Chen","year":"2008","journal-title":"J Cell Mol Med"},{"issue":"3","key":"2019111810035425100_B12","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111810035425100_B13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft versus-host disease with fibrotic features.","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111810035425100_B14","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"2019111810035425100_B15","article-title":"Cyclic protein tyrosine kinase inhibitors.","author":"Das","journal-title":"US patent number 006596746-B1"},{"issue":"9","key":"2019111810035425100_B16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","article-title":"Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.","volume":"19","author":"Roy","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"2019111810035425100_B17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/sj.leu.2404025","article-title":"Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.","volume":"20","author":"Pilot","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"2019111810035425100_B18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment.","volume":"81","author":"Quintas-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2019111810035425100_B19","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111810035425100_B20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111810035425100_B21","first-page":"2546","article-title":"Extension of the cohort analysis for genetic epidemiology program to assess excess risk of cancer.","volume-title":"Am Stat Assoc","author":"Liu","year":"2007"},{"issue":"12","key":"2019111810035425100_B22","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.11831","article-title":"Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"2019111810035425100_B23","unstructured":"Imatinib prescribing information\n          Novartis Pharmaceuticals\n          2010\n          Accessed June 20, 2011\n          \n            http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gleevec_tabs.pdf"},{"issue":"5","key":"2019111810035425100_B24","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation.","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111810035425100_B25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bmt.1705710","article-title":"Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies.","volume":"40","author":"Ferry","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111810035425100_B26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"issue":"9581","key":"2019111810035425100_B27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"2019111810035425100_B28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000318009","article-title":"Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.","volume":"124","author":"Serpa","year":"2010","journal-title":"Acta Haematol"},{"issue":"4","key":"2019111810035425100_B29","first-page":"405","article-title":"Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.","volume":"38","author":"Bhagavathi","year":"2008","journal-title":"Ann Clin Lab Sci"},{"issue":"4","key":"2019111810035425100_B30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12185-010-0546-4","article-title":"Uncommon case of chronic myeloid leukemia with multiple myeloma.","volume":"91","author":"Ide","year":"2010","journal-title":"Int J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/16\/4353\/1342415\/zh804211004353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/16\/4353\/1342415\/zh804211004353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:49:17Z","timestamp":1574074157000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/16\/4353\/28825\/Malignancies-occurring-during-therapy-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,20]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2011,10,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-362889","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,20]]}}}